Table 2.

Distribution of Participants Within Desirability of Outcome Ranking Categories for the CAMERA2 Trial by Treatment Group^a

DOOR Category	Standard Therapy, No. (%) (n = 173)	Combination Therapy, No. (%) (n = 169)
1	99 (57.2)	82 (48.5)
2	35 (20.2)	42 (24.9)
3	11 (6.4)	8 (4.7)
4	0	2 (1.2)
5	28 (16.2)	35 (20.7)

Abbreviations: CAMERA2, Combination Antibiotics for MEthicillin Resistant Staphylococcus aureus; DOOR, desirability of outcome ranking.

^aData on 2 of the DOOR components were missing for 10 participants, who were excluded from the primary analysis: Data on 90-day mortality were missing for 6 participants (1.7%, 3 from each arm), and data on persistent bacteremia were missing for 4 participants (1.1%, 2 from each arm).